Addex Therapeutics Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADXN research report →
About the company
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction.
- CEO
- Timothy Mark Dyer
- IPO
- 2020
- Employees
- 2
- HQ
- Geneva, CH
Price Chart
- Market Cap
- $4.17M
- P/E
- -0.78
- P/S
- 72.88
- P/B
- 2.24
- EV/EBITDA
- -1.19
- Div Yield
- 0.00%
- Gross Margin
- 84.32%
- Op Margin
- -2999.71%
- Net Margin
- -7775.20%
- ROE
- -131.35%
- ROIC
- -74.38%
- Revenue
- $29.97K · -92.58%
- Net Income
- $-6,728,246 · -195.36%
- EPS
- $-6.88 · -181.86%
- Op Income
- $-2,814,598
- FCF YoY
- 61.38%
- 52W High
- $12.05
- 52W Low
- $5.41
- 50D MA
- $6.52
- 200D MA
- $7.61
- Beta
- 1.99
- Avg Volume
- 4.36K
Get TickerSpark's AI analysis on ADXN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Mills Roger | other | 0 |
| Jan 8, 24 | Mills Roger | other | 50,000 |
| Mar 18, 26 | Lawton Vincent Michael | other | 0 |
| Jan 8, 24 | Lawton Vincent Michael | other | 501,598 |
| Oct 5, 22 | Teyssedou Lenaic Nathanael | other | 90,529 |
| May 12, 23 | Teyssedou Lenaic Nathanael | other | 208,974 |
| Jan 8, 24 | Teyssedou Lenaic Nathanael | other | 100,485 |
| Mar 18, 26 | Kalinichev Mikhail | other | 0 |
| Aug 1, 24 | Kalinichev Mikhail | other | 200,000 |
| Mar 18, 26 | Hill Raymond George | other | 0 |
Our ADXN coverage
Recent articles, reports, and earnings notes.
No research on ADXN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADXN report →Similar companies
Peers in the same neighborhood.